ivosidenib Sep 21, 2020 Agios's Tibsovo Trial Fails to Meet Overall Survival Endpoint in IDH1-Mutated Bile Duct Cancer Apr 13, 2020 Agios Pushing Ahead in IDH-Mutated Solid Tumors With Tibsovo, Vorasidenib Premium Oct 1, 2019 Trial Data Reveals Progression Delay in Cholangiocarcinoma with Targeted IDH1 Drug Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
